Shamardl, H., Sadek, S., Ahmed, A. (2023). Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats. test, 12(2), 84-94. doi: 10.21608/fumj.2023.323618
Hanan Shamardl; Sawsan Sadek; Amany Ahmed. "Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats". test, 12, 2, 2023, 84-94. doi: 10.21608/fumj.2023.323618
Shamardl, H., Sadek, S., Ahmed, A. (2023). 'Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats', test, 12(2), pp. 84-94. doi: 10.21608/fumj.2023.323618
Shamardl, H., Sadek, S., Ahmed, A. Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats. test, 2023; 12(2): 84-94. doi: 10.21608/fumj.2023.323618

Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats

Fayoum University Medical Journal
Volume 12, Issue 2, October 2023, Pages 84-94    PDF (579.11 K)
Document Type: Review Articles
DOI: 10.21608/fumj.2023.323618
Authors
Hanan Shamardl1; Sawsan Sadek1; Amany Ahmed2
1Medical Pharmacology department - Faculty of Medicine , Fayoum University
2Medical Pharmacology department - Faculty of Medicine, Fayoum University
Statistics
Article View: 62
PDF Download: 168